SecBot SecBot
8-K ·Filed Apr 30, 2026

ATR

APTARGROUP, INC.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0000896622-26-000090
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The flat core sales and declining margins confirm the emergency medicine headwind is persisting longer than anticipated. Q2 guidance implies a significant sequential improvement but still well below prior year, watch for execution on the injectables GLP-1 ramp and any further destocking commentary on the earnings call. The CEO transition adds medium-term uncertainty.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$118.55
T+0 close · Apr 30, 2026 · via day close
Latest settled
+16.24%
T+60 · $137.81
Vs SPY
+13.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $118.55entry
  2. T+1 · 7mo ago +1.33%α +1.67% · $120.13
  3. T+5 · 6mo ago +2.06%α −0.29% · $120.99
  4. T+20 · 6mo ago −5.21%α −10.47% · $112.38
  5. T+60 · 4mo ago +16.24%α +13.18% · $137.81

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AptarGroup reported Q1 2026 GAAP diluted EPS of $1.12, down 4% YoY from $1.17, and adjusted EPS of $1.19, down 8% YoY at constant currency. Reported sales rose 11% to $982.9M, but core sales were flat, and adjusted EBITDA margin contracted 150 bps to 19.2%. The company guided Q2 2026 adjusted EPS to $1.32-$1.40, below the $1.67 reported in Q2 2025, signaling continued margin pressure from emergency medicine destocking and operational disruptions.

Key Financial Metrics

EPS
$1.12
est $1.15 · -2.6%
Revenue
$982.9M
est $955.9M · +2.8% · +10.8% YoY
Rating
miss
Free Cash Flow
$53.3M

Key Facts

  • GAAP diluted EPS of $1.12 vs $1.17 YoY, a 4% decline
  • Adjusted EPS of $1.19 vs $1.30 YoY at constant currency, down 8%
  • Reported sales +11% to $982.9M, but core sales flat (0%)
  • Adjusted EBITDA margin 19.2% vs 20.7% YoY, down 150 bps
  • Pharma core sales declined 1%; emergency medicine destocking continued
  • Beauty core sales +3%; Closures core sales flat
  • Q2 2026 adjusted EPS guidance $1.32-$1.40, well below Q2 2025's $1.67
  • Operating cash flow improved to $118.7M from $82.7M YoY
  • Returned $131M to shareholders via buybacks and dividends
  • Gael Touya named next CEO effective September 1, 2026

Financial Impact

GAAP EPS declined $0.05 YoY; adjusted EPS declined $0.11 YoY; Q2 guidance midpoint $1.36 is 18.6% below prior year's $1.67

epsrevenuemarginsguidance

Risk Factors

  • Emergency medicine destocking may persist beyond Q2, pressuring Pharma segment
  • Q2 guidance midpoint $1.36 is 18.6% below Q2 2025 actual of $1.67, implying continued earnings contraction
  • Margin compression across all three segments (Pharma -150bps, Beauty -100bps, Closures -270bps)
  • CEO transition effective September 2026 introduces leadership uncertainty
  • Ongoing litigation costs (ARS Pharmaceuticals, Nemera) excluded from adjusted metrics but represent real cash outflow

Market Snapshot

Exchange
NYSE
Sector
Plastics Products, NEC
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Materials & Mining

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000896622-26-000090
Document: atr-20260430.htm0000896622-26-000090
Document: 0000896622-26-000090-index-headers.html0000896622-26-000090
Document: 0000896622-26-000090-index.html0000896622-26-000090
Document: 0000896622-26-000090.txt0000896622-26-000090
8-K Data (Synthetic)0000896622-26-000090

Track record

12 reports on ATR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 2, 202614d ago 144 Neutral 2/10 Entry $143.86 Now $143.17 −0.48% settles Dec 1
  2. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $137.20 Now $143.17 +4.35% settles Nov 30
  3. Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $126.55 Now $143.17 +13.13% settles Nov 20
  4. Sep 21, 20268w ago 8-K Bearish 4/10 Entry $125.45 to $125.77 Now $143.17 −14.13% ▼ −0.26% −0.81% vs SPY
  5. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $128.31 to $121.16 Now $143.17 +11.58% ▼ −5.57% −4.45% vs SPY
  6. Sep 1, 202610w ago 8-K Neutral 2/10 Entry $130.92 to $121.44 Now $143.17 +9.36% ▼ −7.24% −8.42% vs SPY
  7. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $135.78 to $128.31 Now $143.17 +5.44% ▼ −5.50% −6.10% vs SPY
  8. Aug 4, 202614w ago Insider Cluster Neutral 3/10 Entry $136.18 to $130.92 Now $143.17 +5.13% ▼ −3.86% −2.62% vs SPY
  9. Jul 17, 202617w ago Court Ruling Bullish 5/10 Entry $129.45 to $131.74 Now $143.17 +10.60% ▲ +1.77% −2.35% vs SPY
  10. Jun 10, 202622w ago Insider Cluster Neutral 2/10 Entry $114.67 to $124.45 Now $143.17 +24.85% ▲ +8.53% +4.91% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026